These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 2787958)

  • 1. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.
    Landefeld CS; Goldman L
    Am J Med; 1989 Aug; 87(2):144-52. PubMed ID: 2787958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of major hemorrhage for outpatients treated with warfarin.
    McMahan DA; Smith DM; Carey MA; Zhou XH
    J Gen Intern Med; 1998 May; 13(5):311-6. PubMed ID: 9613886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.
    Beyth RJ; Quinn LM; Landefeld CS
    Am J Med; 1998 Aug; 105(2):91-9. PubMed ID: 9727814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.
    Fihn SD; McDonell M; Martin D; Henikoff J; Vermes D; Kent D; White RH
    Ann Intern Med; 1993 Apr; 118(7):511-20. PubMed ID: 8280198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions.
    Landefeld CS; Rosenblatt MW; Goldman L
    Am J Med; 1989 Aug; 87(2):153-9. PubMed ID: 2757055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study.
    Jun M; James MT; Manns BJ; Quinn RR; Ravani P; Tonelli M; Perkovic V; Winkelmayer WC; Ma Z; Hemmelgarn BR;
    BMJ; 2015 Feb; 350():h246. PubMed ID: 25647223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy.
    DeEugenio D; Kolman L; DeCaro M; Andrel J; Chervoneva I; Duong P; Lam L; McGowan C; Lee G; DeCaro M; Ruggiero N; Singhal S; Greenspon A
    Pharmacotherapy; 2007 May; 27(5):691-6. PubMed ID: 17461704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study.
    Wang SV; Franklin JM; Glynn RJ; Schneeweiss S; Eddings W; Gagne JJ
    BMJ; 2016 May; 353():i2607. PubMed ID: 27221664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention.
    Landefeld CS; Beyth RJ
    Am J Med; 1993 Sep; 95(3):315-28. PubMed ID: 8368229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota.
    Gitter MJ; Jaeger TM; Petterson TM; Gersh BJ; Silverstein MD
    Mayo Clin Proc; 1995 Aug; 70(8):725-33. PubMed ID: 7630209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis.
    Abdelhafiz AH; Myint MP; Tayek JA; Wheeldon NM
    Clin Ther; 2009 Jul; 31(7):1534-9. PubMed ID: 19695402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bleeding-related hospital admissions and 30-day readmissions in patients with non-valvular atrial fibrillation treated with dabigatran versus warfarin.
    Lau WCY; Li X; Wong ICK; Man KKC; Lip GYH; Leung WK; Siu CW; Chan EW
    J Thromb Haemost; 2017 Oct; 15(10):1923-1933. PubMed ID: 28748652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting.
    Kawai H; Watanabe E; Yamamoto M; Harigaya H; Sano K; Takatsu H; Muramatsu T; Naruse H; Sobue Y; Motoyama S; Sarai M; Takahashi H; Arakawa T; Kan S; Sugiura A; Murohara T; Ozaki Y
    J Cardiol; 2015 Mar; 65(3):197-202. PubMed ID: 25266323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
    J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.